Multivitamins and the bulk of nutritional supplements do little to protect heart health, in some cases increasing a person’s risk for CV events, an analysis published in the Annals of Internal Medicine has found.
A lack of formal training in nutrition could significantly limit how physicians practice, according to an editorial published in JAMA Internal Medicine this month, in some cases leading them to recommend risky treatments to patients in lieu of dietary counseling that might be just as effective.
A bariatric surgeon at the Ohio State Wexner Medical Center is advocating for a new set of clinical guidelines that would extend eligibility for weight loss surgery to thousands more patients struggling with their weight.
Fear-based “fake news” about statin therapy is driving non-adherence to the drugs in the U.S., according to an editorial published in JAMA Cardiology June 26, fostering a culture of mistrust and misinformation that could easily deter heart patients from a treatment that might be beneficial to them.
Body fat distribution could be a key predictor of heart disease risk in postmenopausal women, according to a July 1 study that found “apple”-shaped women are more prone to CVD than their “pear”-shaped counterparts.
Inadequate fruit and vegetable consumption contributes to nearly 2 million CV-related deaths each year, according to research presented at Nutrition 2019, the American Society for Nutrition’s annual meeting, in Baltimore.
A collaboration between cardiologists and dentists at the Karolinska Institutet in Sweden has linked undetected glucose disorders like diabetes to an increased risk of myocardial infarction and periodontitis, a severe gum disease.
Harvard researchers have identified three health interventions that, if implemented and followed closely over the next quarter-century, could prevent up to 94 million early deaths from noncommunicable diseases like CVD.
Red and white meat have equally harmful effects on blood cholesterol levels, according to research published in the American Journal of Clinical Nutrition, contradicting the popular idea that lighter proteins like chicken are more heart-healthy than their counterparts like beef and lamb.
An updated cost-effectiveness analysis of evolocumab suggests that while treatment with the PCSK9 inhibitor may always be somewhat costly, it remains effective in hard-to-treat patients and its reduced list price meets cost-effectiveness thresholds across a range of CV events in patients with very-high-risk atherosclerotic CVD.